J
Jerome F. Daanen
Researcher at AbbVie
Publications - 54
Citations - 1200
Jerome F. Daanen is an academic researcher from AbbVie. The author has contributed to research in topics: TRPV1 & Sexual dysfunction. The author has an hindex of 20, co-authored 54 publications receiving 1158 citations. Previous affiliations of Jerome F. Daanen include Abbott Laboratories.
Papers
More filters
Journal ArticleDOI
Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia
Prisca Honore,Prasant Chandran,Gricelda Hernandez,Donna M. Gauvin,Joseph P. Mikusa,Chengmin Zhong,Shailen K. Joshi,Joseph R. Ghilardi,Molly A. Sevcik,Ryan M. Fryer,Jason A. Segreti,Patricia N. Banfor,Kennan C. Marsh,Torben R. Neelands,Erol K. Bayburt,Jerome F. Daanen,Arthur Gomtsyan,Chih Hung Lee,Michael E. Kort,Regina M. Reilly,Carol S. Surowy,Philip R. Kym,Patrick W. Mantyh,James P. Sullivan,Michael F. Jarvis,Connie R. Faltynek +25 more
TL;DR: ABT‐102, which is a potent and selective TRPV1 antagonist, is effective in blocking nociception in rodent models of inflammatory, post‐operative, osteoarthritic, and bone cancer pain and its analgesic efficacy supports its advancement into clinical studies.
Journal Article
ABT-089 (2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride): II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys
Michael W. Decker,Anthony W. Bannon,Peter Curzon,Karen L. Gunther,Jorge D. Brioni,Mark W. Holladay,Nan-Horng Lin,Yihong Li,Jerome F. Daanen,Jerry J. Buccafusco,Mark A. Prendergast,William J. Jackson,Stephen P. Arneric +12 more
TL;DR: In rats and monkeys, acute administration of ABT-089 modestly improved the delayed matching-to-sample performance of mature, adult monkeys and more robustly improved performance in aged monkeys and was not accompanied by changes in response latencies.
Journal ArticleDOI
Pharmacology of Modality-Specific Transient Receptor Potential Vanilloid-1 Antagonists That Do Not Alter Body Temperature
Regina M. Reilly,Heath A. McDonald,Pamela S. Puttfarcken,Shailen K. Joshi,La Geisha Lewis,Madhavi Pai,Pamela H. Franklin,Jason A. Segreti,Torben R. Neelands,Ping Han,Jun Chen,Patrick W. Mantyh,Joseph R. Ghilardi,Teresa M. Turner,Voight Eric,Jerome F. Daanen,Robert G. Schmidt,Arthur Gomtsyan,Michael E. Kort,Connie R. Faltynek,Philip R. Kym +20 more
TL;DR: Comparison of the in vitro pharmacological properties of these TRPV1 antagonists with their in vivo effects on core body temperature confirms and expands earlier observations that acid-sparing TRPv1 antagonists do not significantly increase coreBody temperature.
Journal ArticleDOI
Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: Effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice
Mark W. Holladay,Hao Bai,Yihong Li,Nan-Horng Lin,Jerome F. Daanen,Keith B. Ryther,James T. Wasicak,John F. Kincaid,Yun He,Anne-Marie Hettinger,Peggy Huang,David J. Anderson,Anthony W. Bannon,Michael J. Buckley,Jeffrey E. Campbell,Diana L. Donnelly-Roberts,Karen L. Gunther,David J.B. Kim,Theresa A. Kuntzweiler,James P. Sullivan,Michael W. Decker,Stephen P. Arneric +21 more
TL;DR: Analogs of A-98593 and its enantiomer ABT-594 with diverse substituents on the pyridine ring were prepared and tested for affinity to nicotinic acetylcholine receptor binding sites in rat brain and for analgesic activity in the mouse hot plate assay.
Journal ArticleDOI
Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.
Guo Zhu Zheng,Pramila Bhatia,Jerome F. Daanen,Teodozyj Kolasa,Meena V. Patel,Steven P. Latshaw,Odile F. El Kouhen,Renjie Chang,Marie E. Uchic,Loan N. Miller,Masaki Nakane,Sonya G. Lehto,Marie P. Honore,Robert B. Moreland,Jorge D. Brioni,Andrew O. Stewart +15 more
TL;DR: SAR (structure-activity relationship) studies of triazafluorenone derivatives as potent mGluR1 antagonists are described and compounds 1n and 1n demonstrated full efficacy in various in vivo animal pain models.